NICE Surgical Solutions, a Singapore-based clinical-stage medical device company focused on advancing full intracorporeal anastomosis surgical technologies, has secured a US patent for its innovative purse-string stapler.
The newly granted patent covers the efficient application of a purse-string suture around the tissue adjacent to the open lumen during colorectal surgery. This enables the effective closure of the colon, providing a full intracorporeal anastomosis after the surgery.
According to NICE Surgical, the patented technology enables minimally invasive colorectal surgery without requiring an abdominal incision, which remains common in current practice. By reducing the need for surgical incisions, the device could improve procedural efficiency and lower the risk of surgical site infections.
Haim Brosh, CEO of Trendlines, said, “This patent is a testament to the dedication and ingenuity of the research and development team at NICE Surgical. With NICE Surgical’s development progression, including human clinical studies by Q4 2026, this milestone further strengthens our validated technology.”
Eric Haas, co-founder and inventor of the technology and Chief of Colorectal Surgery at Houston Methodist Hospital, said medical innovation transforms scientific discovery into better patient outcomes.
“I am excited that the grant of this patent acknowledges the novelty, ingenuity and potential societal value of our medical innovation,” he added.
NICE Surgical is a portfolio company of Trendlines Medical Singapore, a subsidiary of The Trendlines Group, an investment company focused on medtech and agrifood innovation.
The company is developing a stapling device designed to perform two key functions in colorectal surgery: dividing the bowel at the proximal and distal resection points while simultaneously placing a purse-string suture to prepare the bowel for intracorporeal anastomosis.
